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Case Report: The Complexities of
Managing Medications and the
Importance of Deprescribing
Anticholinergics in Older Adults
Taylor Elliott 1, Lynne Eckmann2 and Daniela C. Moga1,3,4*
1Department of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky, Lexington, KY, United States,
2PRO2RX LLC Pharmacy Consulting Services, Lexington, KY, United States, 3Department of Epidemiology, College of Public
Health, University of Kentucky, Lexington, KY, United States, 4Sanders-Brown Center on Aging, University of Kentucky,
Lexington, KY, United States
Potentially inappropriate anticholinergic medications (including over-the-counter
products), polypharmacy, and the existence of communication barriers among
members of the interprofessional team frequently contribute to clinical complexity in
older adults. We present the case of a frail 86-year old female from the perspective of
a community pharmacist managing outpatient medications and transitions of care. CD’s
past medical history is significant for dementia, multiple falls, recurrent urinary tract
infections, depression, cardiac arrhythmia, macular degeneration, chronic pain,
depression, and cerebrovascular disease.
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INTRODUCTION
CD, the patient discussed in this case report, is a frail 86-year-old female with diagnosed dementia
taking several medications to address multiple chronic conditions. CD’s past medical history is
significant for dementia, multiple falls, recurrent urinary tract infections (UTIs), depression, cardiac
arrhythmia, macular degeneration, chronic pain, depression, and cerebrovascular disease. Despite
participating in a medication management program with access to a board certified geriatric
pharmacist available for consultation at all times, as well as having around-the-clock caregivers
and a specialized team of health care providers, this patient’s trajectory illustrates the complexities of
managing medications and transitions of care in older adults with dementia, as well as the
importance of carefully assessing and deprescribing medications with anticholinergic properties.
CD enrolled in a medication management program on 03/27/2020. This program is an innovative
community program in Kentucky providing pharmacy services that promote and prolong
independent living, as well as control ongoing prescription costs. The goals of the program are
to decrease the number of unwanted effects frommedications in order to prevent falls, fractures, and
other adverse events that may lead to loss of independence. As a note, while some insurance plans
include basic medication reviews, the comprehensive services included in this program are not
covered by Medicare or other insurance. Upon enrollment, the patient’s entire medication regimen -
including over-the-counter medications, vitamins, and herbal supplements-is analyzed to identify
potentially inappropriate medications (e.g., anticholinergics and benzodiazepines) and drug-drug
interactions. Prescribers (i.e., primary care providers and specialists treating chronic disease states)
are contacted at enrollment and as needed thereafter to recommend medication therapy changes.
Each week, a seven-day supply of chronic medications (including over-the-counters and vitamins
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/herbal supplements) is prepared and delivered to the patient’s
residence. After the weekly visit, the pharmacist reviews the
previous week’s medication supply for adherence, and follow-
up is made with family members, caregivers, and/or health care
providers as appropriate. In addition, acute medication changes
are immediately addressed, and same day reconciliations
are made.
The goals of this case report are threefold: 1) to demonstrate the
importance of deprescribing inappropriate anticholinergic
medications, 2) to highlight the consequences of viewing over-
the-counter medications as benign, and 3) to emphasize the critical
need for adequate transitions of care and communication among
all members of the interprofessional team.
CASE DESCRIPTION
The patient discussed in this case report is a frail 86-year-old
female with a past medical history significant for dementia,
multiple falls, recurrent urinary tract infections (UTIs),
depression, cardiac arrhythmia, macular degeneration, chronic
pain, depression, and cerebrovascular disease. CD lives
independently at home along with her adult daughter who
previously suffered a traumatic brain injury. CD was enrolled in
a medication management program on 03/27/2020. At that time,
the patient and her daughter had a caregiver assisting for 3 h every
day. The caregiver ensured the appropriate medications were taken
in the morning and organized the evening doses for self-
administration. However, the patient was unable to safely self-
administer medications and was therefore referred to the
medication management program. Upon enrollment, an
electronic medication box that rotates and alarms at set times
was provided to help manage medications. CD had nine chronic
medications at enrollment (Table 1), including one anticholinergic
(loratadine). Although loratadine is an anticholinergic medication,
it is considered a safer alternative when an antihistaminic is
necessary to prescribe. None of CD’s initially reviewed
medications were potentially inappropriate for her based on the
2019 Beers List (By the 2019 American Geriatrics Society Beers
Criteria® Update Expert Panel, 2019). The timeline of events
relevant for this case is described below, and a summary is
included in the supplementary table (Supplementary Table S1).
• April 20, 2020: CD’s initially reported medication list remained
unchanged until this time. The caregiver alerted the pharmacist
that the patient was having trouble sleeping. Melatonin was
changed from a quick-dissolve tablet to a capsule due to the
patient’s inability to appropriately use medications by
sublingual route.
• April 21, 2020: Upon scheduled delivery, the caregiver notified
the pharmacist the patient had experienced a fall the weekend
prior and injured her shoulder. The caregiver also mentioned a
suspected UTI due to the patient having cloudy urine. The
caregiver contacted the primary care provider (PCP) about the
patient’s signs and symptoms. In order to limit exposure during
the COVID-19 pandemic, the PCP requested a urine sample to
be dropped off in place of a traditional appointment. The
following day, the PCP confirmed the presence of a UTI and
prescribed cephalexin 250 mg capsules by mouth three times
daily for 7 days. The pharmacist simultaneously initiated a 30-
TABLE 1 | Initial Medication List (as reported on March 30, 2020)
Patient: CD (XX/XX/1934) Initial Medication List (as reported on March 30, 2020)
Medication Dose 9 AM Noon 6 PM 9 PM
Lisinopril 5 mg 1 daily 1
Apixaban 2.5 mg 1 twice daily 1 1
Metoprolol succinate 50 mg 1 daily 1
Donepezil 5 mg 1 daily 1
Simethicone 80 mg Chew 1 three times daily 1 1 1
Loratadine 10 mga 1 daily 1
Preservision 2 daily 2
Trazodone 50 mg 2 daily 2
Melatonin 10 mg 1 daily at bedtime 1
Potential Drug-Drug Interaction Risk Rating Summary of Interaction
Donepezil (Acetylcholinesterase Inhibitors) - Loratadine (Anticholinergic
Agents)
C Acetylcholinesterase Inhibitors may diminish the
therapeutic effect of Anticholinergic Agents.
Anticholinergic Agents may diminish the therapeutic
effect of Acetylcholinesterase Inhibitors.
Donepezil (Acetylcholinesterase Inhibitors) - Metoprolol (Beta-Blockers) C Acetylcholinesterase Inhibitors may enhance the
bradycardic effect of Beta-Blockers.
Donepezil (Bradycardia-Causing Agents) - Metoprolol (Bradycardia-
Causing Agents)
C Bradycardia-Causing Agents may enhance the
bradycardic effect of other Bradycardia-Causing
Agents.
Loratadine (CNS Depressants) - Trazodone (CNS Depressants) C CNS Depressants may enhance the adverse/toxic
effect of other CNS Depressants.
a anticholinergic properties.
Risk Ratings: A  No known interaction, B  No action needed, C = Monitor therapy, D  Consider therapy modification, X  Avoid combination.
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days course of probiotics in an attempt to prevent a Clostridium
difficile infection. In addition, the PCP placed CD’s donepezil
on hold and expressed concern that the medication may be
contributing to the patient’s falls and lack of appetite. At the
time of the initial writing of this report, the cause of CD’s fall
was unknown. Possible causes include drug-drug interactions
due to polypharmacy (see Table 1), UTI, and decreased
cognitive function.
• April 24, 2020: The caregiver notified the pharmacist that the
acetaminophen ER 650 mg tablets and lidocaine patches were
not sufficiently relieving the patient’s pain that resulted from her
fall. On April 28, 2020, the patient’s PCP prescribed tramadol
50 mg tablets by mouth three times daily as needed. At this time,
the patient transitioned to 24-h, around-the-clock care. The
original caregiver extended her daytime hours, and additional
help was hired for evening assistance.
• May 12, 2020: The caregiver notified the pharmacist about the
patient’s unimproved state – she was still confused, lethargic,
and had poor appetite. The pharmacist suggested UTI test
strips to evaluate the potential of a refractory UTI from April
22, 2020.
• May 13, 2020: The test strips were delivered to the patient’s
residence by the pharmacist. The patient tested positive for
nitrites and leukocytes. The pharmacist suggested a urinalysis,
and culture and sensitivity after learning of the positive result.
• May 14, 2020: The PCP prescribed sulfamethoxazole/
trimethoprim 400/80 mg by mouth two times daily for
10 days and instructed the caregiver to re-check for
infection three days after completing the course of antibiotics.
• May 18, 2020: Upon scheduled delivery, the pharmacist
incidentally noticed four bottles of liquid
diphenhydramine that were not supplied by the pharmacy
or recorded on the patient’s initial medication list. The
caregiver informed the pharmacist she had seen it
advertised for sleep. According to the caregiver, the
patient had been taking 50 mg by mouth nightly for
approximately one week. However, the exact initiation
date remains unclear, as the diphenhydramine was not
cleared by the pharmacist prior to use. The pharmacist
discussed the potential adverse effects of anticholinergic
medications in older adults with dementia (including
increased risks for falls, urinary retention, and confusion)
and suggested tapering the diphenhydramine to 25 mg
nightly for a short period followed by discontinuation.
Diphenhydramine is on the 2019 Beers List as a
potentially inappropriate medication in due to its highly
anticholinergic properties (Salahudeen et al., 2015; By the
2019 American Geriatrics Society Beers Criteria® Update
Expert Panel, 2019).
• May 21, 2020: The patient was prescribed megestrol 400 mg/
10 ml bymouth daily for appetite stimulation, along with a refill
for tramadol. The prescriptions were sent in by a palliative care
provider. Of note, a prior authorization was required for the
megestrol, so the patient did not receive the medication prior to
hospitalization of May 27, 20 (see below). In addition, the
pharmacist had concerns that another medication was being
added to CD’s already complex regimen without trying to find
the root cause of her symptoms. In addition, megestrol is listed
on the 2019 Beers List for increased risk of thrombotic events
and possibly death in older adults.
• May 22, 2020: The caregiver alerted the pharmacist of the
patient’s consistently low blood pressure (∼90/60 mmHg). The
nurse practitioner on the palliative care team instructed the
patient’s metoprolol be held. Upon review of the patient’s
medication list, the pharmacist also suggested holding
lisinopril and contacting the provider to further evaluate. At
this time, the caregiver confirmed diphenhydramine was
tapered and discontinued.
• May 27, 2020: CD’s conditioned continued to decline, and she
was admitted to the hospital with a diagnosis of sepsis
secondary to Gram-negative UTI. She also had hypokalemia.
CD was treated with intravenous antibiotics while inpatient.
• June 01, 2020: CD was discharged from the hospital at 10:00 pm
with hospice referral. The patient was sent home with three
prescriptions (a new order for potassium and decreased doses
of metoprolol and lisinopril) from the hospital’s “Meds to Beds”
service.
• June 02, 2020: The pharmacist contacted the caregiver to check
in and was informed of the patient’s discharge the night before.
The pharmacist then attempted to contact the hospice nurse
twice but did not receive a call back until after the home visit
was already completed. Upon delivery, the pharmacist found
handwritten notes from the hospice nurse on the medication
list provided by the medication management program. The
pharmacist reconciled the notes with the discharge paperwork
from the hospital to ensure accuracy.
• June 08, 2020: lisinopril, metoprolol, and pravastatin were
all discontinued per hospice. Per the pharmacist’s
recommendations, CD’s doses of Eliquis were spaced to 9:00
am and 9:00 pm (rather than 9:00 am and 6:00 pm) and the oral
potassium was changed to 20 mEq twice daily rather than
40 mEq once daily to reduce GI upset (Table 2).
At the time this case report was written in July 2020, the
pharmacist had suggested multiple medication changes to the
hospice team and had also requested a BMP to check CD’s
potassium level. She had not yet heard back. When revisions
were made in February 2021, CD’s clinical status had improved
significantly. The pharmacist’s recommendations where accepted
(including the addition of potassium), the patient no longer
required hospice services, and memantine was initiated to slow
further cognitive decline.
DISCUSSION
The patient discussed in this case report illustrates the
complexities of managing medications in older adults with
dementia. The potentially harmful use of an anticholinergic
over-the-counter medication, the presence of polypharmacy,
the patient’s impaired cognitive function, the manifestation
of UTI, and the incidence and risk of recurrent injurious falls
are all interconnected. Communication barriers among
members of the interprofessional team and the global
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COVID-19 pandemic further complicated CD’s clinical
course (Figure 1).
Anticholinergics are listed on the American Geriatrics Society’s
2019 Beers List as potentially inappropriate medications for
older adults (By the 2019 American Geriatrics Society Beers
Criteria® Update Expert Panel, 2019). Even as single agents,
they may contribute to negative events such as falls, delirium,
urinary retention, and decreased cognitive function. Despite these
risks, as many as one in every two older Americans takes an
anticholinergic medication. Because over-the-counter medication
use is not easily captured in healthcare data, it is likely this
statistic is underestimated. Non-prescription medications like
diphenhydramine, doxylamine, and dimenhydrinate are
commonly purchased and chronically used to treat conditions
such as allergies, sleeplessness, and motion sickness (Holden et al.,
2019). In fact, one study showed that more than half of the 1,025
participants aged 65 and older who were interviewed reported
using a potentially inappropriate over-the-counter medication
containing diphenhydramine or doxylamine to improve sleep
within the past 30 days. Those participants were also less likely
to be aware of the associated safety risks (Sudershan and Kamath,
2017).
Because over-the-counter medications like diphenhydramine
and doxylamine are so easily accessible, they are often perceived
as benign. Viewing them as low risk, patients and their
caregivers frequently fail to report their use, as in the case of
CD. This issue can go unnoticed for long periods of time and
lead to new health problems or perpetuate existing issues. CD’s
nightly use of diphenhydramine potentially contributed to her
complicated clinical course through multiple mechanisms. First,
as a member of the anticholinergic class, diphenhydramine
independently increases fall risk. Because the exact initiation
date remains unclear, it is difficult to determine whether the
diphenhydramine contributed to the injurious fall that occurred
the weekend prior to April 21, 2020. Given the widespread
availability of these agents, it is possible they may have
contributed to CD’s previous falls, and without pharmacist
intervention, they certainly would have contributed to CD’s
risk for recurrent falls. Secondly, because diphenhydramine
leads to urinary retention, it may have promoted the growth
of unwanted bacteria that are normally flushed out during
micturition. Subsequently, the manifestation of a urinary
tract infection may have led to increased confusion and/or
low blood pressure and further increased fall risk as a result.
Third, anticholinergic medications like diphenhydramine have
been shown to exacerbate pre-existing cognitive impairment, as
they counteract the therapeutic effect of medications used to
treat dementia and other similar conditions. In CD’s case, the
TABLE 2 | Updated Medication List (as reported on June 8, 2020).
Patient: CD (XX/XX/1934) Updated Medication List (as reported on June 8, 2020)
Medication Dose 9 AM Noon 6 PM 9 PM
Eliquis 2.5 mg 1 twice daily 1 1
Potassium Cl 20 mEq 1 twice daily with food and water 1 1
Loratadine 10 mga 1 daily
Preservision 2 daily 2
Trazodone 50 mg 2 daily 2
Melatonin 10 mg Dissolve 1 tablet at bedtime 1
Trubiotic 1 daily for 60 d 0 or 1
Tramadolb 50 mg 1 three times daily as needed for pain
Potential Drug-Drug Interaction Risk Rating Summary of Interaction
Loratadine (CNS Depressants) - Potassium Chloride Xc Anticholinergic Agents may enhance the
ulcerogenic effect of Potassium Chloride.
Loratadine (CNS Depressants) - Tramadol (Opioid Agonists) Dd CNS Depressants may enhance the CNS
depressant effect of Opioid Agonists.
Tramadol (Opioid Agonists) - Trazodone (CNS Depressants) Dd CNS Depressants may enhance the CNS
depressant effect of Opioid Agonists.
Tramadol (Serotonergic Opioids (High Risk)) - Trazodone (Serotonergic Non-Opioid
CNS Depressants)
Dd Serotonergic Non-Opioid CNS Depressants
may enhance the CNS depressant effect of
Serotonergic Opioids (High Risk).
Serotenergic Non-Opioid CNS Depressants
may enhance the serotonergic effect of
Serotonergic Opioids (High Risk). This could
result in serotonin syndrome.
Loratadine (CNS Depressants) - Trazodone (CNS Depressants) C CNS Depressants may enhance the adverse/
toxic effect of other CNS depressants.
Bolded  new,
a anticholinergic properties,
b on the Beers 2019 list.
cAgents with greater anticholinergic effects are likely of more concern than agents with lesser anticholinergic effects like loratadine.
dCD uses tramadol very infrequently and only as needed.
Risk Ratings: A  No known interaction, B  No action needed, C  Monitor therapy, D  Consider therapy modification, X  Avoid combination.
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diphenhydramine was likely negating the potential benefit of
donepezil. Not surprisingly, dementia is also considered an
independent risk factor for falling in older adults.
While the use of a potentially harmful over-the-counter
anticholinergic medication potentially contributed to CD’s
clinical issues, it was not the only risk factor. Polypharmacy,
which is commonly defined by the use of five or more
medications daily, leads to an array of unwanted
consequences: increased healthcare costs, adverse drug events,
drug-drug and drug-disease interactions, medication non-
adherence, decreased functional status, increased cognitive
impairment, increased falls (and therefore increased morbidity
and mortality), increased urinary incontinence, and increased
incidence of malnourishment (Maher et al., 2013). Upon
enrollment in the medication management program, the
patient reported taking nine medications per day with three
different dosing times. While each of these medications may
have been indicated for a specific disease state, the risk of harm
and adverse events has been shown to increase with each added
medication (Rudolph, 2008; Moga et al., 2019).
Lastly, the lack of adequate transitions of care and
communication among all members of the interprofessional
team likely also contributed to the patient’s clinical course.
Within the first three months of CD’s enrollment in the
medication management program, she received care from her
PCP, the palliative care team, the inpatient team during her
hospital stay, the pharmacist, and her caregivers. Communicating
the necessary information in a timely fashion to all participating
healthcare providers proves itself nearly impossible, especially
considering the lack of interfacing between electronic health
record (EHR) systems. In addition, the global COVID-19
pandemic increased these difficulties, as CD was unable to
seek traditional face-to-face outpatient care.
Unfortunately, the use of potentially inappropriate
anticholinergic medications (including over-the-counter
products), polypharmacy, and the lack of communication
among the interprofessional healthcare team are widespread
issues not limited to this patient. Bringing awareness to these
problems is a crucial first step in improving health outcomes and
prolonging independent living among older adults. Pharmacists
providing medication management programs can play a key role
as mediators between providers and patients and their caregivers
in order to improve quality of care. As medication experts,
pharmacists can provide medication therapy recommendations
to prescribers, as well as provide appropriate education to
patients and their caregivers. In the case of CD, the
pharmacist’s continuity of care led to the discontinuation of
diphenhydramine and potentially prevented further adverse
events, including additional falls.
Strengths
This case report serves as an educational tool for health care
professionals managing the care of similar patient populations. It
will hopefully encourage changes in clinical and community
practice, including more deprescribing of potentially
inappropriate medications, like anticholinergics and more
vigilance during transitions of care.
Limitations
One of the main limitations of this case report was the pharmacist’s
lack of access to CD’s EHR. The inability to view patient care
notes and lab results made it difficult to see the complete medical
picture. However, this highlights the current reality of community
pharmacists and demonstrates the need for improvement. Another
limitation of this case report is that it is not generalizable to patients
who aren’t enrolled in a medication management program. Older
adults attempting to self-manage theirmedications are at even greater
risk for adverse effects of medications.
PATIENT PERSPECTIVE
Note: Due to CD’s cognitive impairment, we requested the
caregiver’s perspective in lieu of the patient perspective.
I had previously been a caregiver for the client for a short
time after she returned home from hiatal hernia surgery in
July 2019. In March 2020, I came back into her home after
another caregiver left. Caregiving hours were set for 3 h
daily. Shortly after coming back, the global COVID-19
pandemic really became something scary in the
United States. I was relieved to have medication
management support added by the client’s POA due to
caregiver reported concerns of patient’s inability to self-
manage and patient’s daughter mixing up medication
planners during unsupervized times of the day. After the
client’s daughter reported a fall, I reached out to the doctor. I
was instructed to treat soreness with acetaminophen and
monitor since no major injuries were observed. After coming
back from being off over the weekend, patient’s daughter
reported three falls. She also stated the ambulance came, but
her mother refused to go the hospital. I believe she was
scared of COVID-19. The next day, I called her physician to
report the fall and right shoulder pain. We were able to set up
FIGURE 1 | Factors associated with the risk of falls.
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a telehealth appointment since I could assist using my
smartphone. Her doctor did not want to prescribe pain
medication because of risk of falls and adverse effects and
previous history. He did make a referral for palliative care
evaluation, but this took weeks. I also reported concerns of
increased confusion and hallucinations and questioned history
of urinary tract infections. I was instructed to pick up sterile
urine cups at the office and return sample. I did not hear back
from the office, but I was informed by the pharmacist when an
antibiotic had been prescribed and medication planner was
updated. Unfortunately, the client did not seem to be
improving. After another call to the doctor, due to client’s
continued shoulder pain, the doctor prescribed tramadol.
During scheduled weekly delivery, the pharmacist discovered
over-the-counter diphenhydramine liquid had been added to
help with sleep and explained this could worsen confusion,
increase risk of falls, and cause urinary retention and should be
discontinued. I appreciated the information, as I did not realize
something promoted over the counter for sleep could cause these
problems. The pharmacist suggested and delivered over the
counter strips to see if infection was still there and
recommended follow up with physician if positive. I called the
office since the test showed positive, and the doctor called in a
different antibiotic and asked me to check urine again with the
strips after she finished. Unfortunately, the client continued
declining and was admitted to the hospital with sepsis and low
potassium. Since the client has come back home, hospice is in place
and we continue to work through these challenges.
Three concerns I noted during the experience include:
difficulty navigating the health system with multiple phone
calls and delayed follow up return calls, complex situation
complicated by COVID-19 and offices shifting to telehealth,
and communication challenges due to multiple factors.
FUTURE DIRECTIONS
Pharmacists, particularly those leading comprehensive medication
management programs, are uniquely positioned to help incorporate
non-pharmacologic fall risk reduction strategies. For example,
patients like CD could undoubtedly benefit from physical
therapists to improve gait and stability, nutritionists to enhance
diet (i.e., calcium intake), and optometrists to assist with vision
impairment. Serving as the patient’s liaison to health care providers
of this sort could undoubtedly improve health outcomes and quality
of life. In addition, pharmacists can help reduce environmental risk
factors for falls by suggesting sensible shoes, increased lighting in
dimly lit areas, assistive devices where appropriate, and removal of
tripping hazards such as throw rugs.
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